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Objectives : Secretoneurin is produced in neuroendocrine cells, 
and the myocardium and circulating secretoneurin levels provide 
incremental prognostic information to established risk indices in 
cardiovascular disease. As myocardial dysfunction contributes to 
poor outcome in critically ill patients, we wanted to assess the 
prognostic value of secretoneurin in two cohorts of critically ill 
patients with infections.
Design: Two prospective, observational studies.
Setting: Twenty-four and twenty-five ICUs in Finland.
Patients: A total of 232 patients with severe sepsis (cohort #1) 
and 94 patients with infections and respiratory failure (cohort #2).
Interventions: None.
Measurements and Main Results: We measured secretoneurin 
levels by radioimmunoassay in samples obtained early after ICU 
admission and compared secretoneurin with other risk indices.  
In patients with severe sepsis, admission secretoneurin levels (loga-
rithmically transformed) were associated with hospital mortality (odds 
ratio, 3.17 [95% CI, 1.12–9.00]; p = 0.030) and shock during the 
hospitalization (odds ratio, 2.17 [1.06–4.46]; p = 0.034) in analy-
ses that adjusted for other risk factors available on ICU admission. 
Adding secretoneurin levels to age, which was also associated with 
hospital mortality in the multivariate model, improved the risk predic-
tion as assessed by the category-free net reclassification index: 0.35 
(95% CI, 0.06–0.64) (p = 0.02). In contrast, N-terminal pro–B-type 
natriuretic peptide levels were not associated with mortality in the 
multivariate model that included secretoneurin measurements, and 
N-terminal pro–B-type natriuretic peptide did not improve patient 
classification on top of age. Secretoneurin levels were also associ-
ated with hospital mortality after adjusting for other risk factors and 
improved patient classification in cohort #2. In both cohorts, the opti-
mal cutoff for secretoneurin levels at ICU admission to predict hospital 
mortality was ≈ 175 pmol/L, and higher levels were associated with 
mortality also when adjusting for Simplified Acute Physiology Score II 
and Sequential Organ Failure Assessment scores.
Conclusions: Secretoneurin levels provide incremental information 
to established risk indices for the prediction of mortality and shock 
in critically ill patients with severe infections. (Crit Care Med 2016; 
XX:00–00)
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in critical illness require 24 hours of data collection (2, 3), cur-
rently, no test is available to identify high-risk patients at ICU 
admission. Cardiovascular biomarkers could prove useful for 
early risk assessment in critically ill patients with infections, but 
the established biomarkers N-terminal pro–B-type natriuretic 
peptide (NT-proBNP) and high-sensitivity troponin T (hs-TnT) 
seem to lack the desired prognostic accuracy when measured at 
ICU admission (4, 5). Accordingly, novel cardiovascular biomark-
ers are needed to improve the risk assessment on ICU admission.
Secretoneurin is a 33-amino acid peptide derived from the 
proprotein secretogranin II, which is produced in the myocar-
dium and in neuroendocrine cells (6, 7). Circulating secreto-
neurin levels increase during profound systemic and myocardial 
stress (7, 8), and secretoneurin levels are also increased by renal 
failure (9). The potential of secretoneurin to integrate informa-
tion from the cardiovascular, renal, and neuroendocrine system 
may explain the potent prognostic information recently dem-
onstrated for secretoneurin in patients with cardiovascular dis-
ease (CVD) (9). In patients with acute heart failure and after 
ventricular arrhythmia–induced cardiac arrest, secretoneurin 
provided additional prognostic information to clinical variables 
and norepinephrine, NT-proBNP, and hs-TnT levels. Other 
groups have also found secretoneurin to predict outcome after 
cardiac arrest (10). In contrast, admission secretoneurin levels 
were not associated with outcome in patients with acute exacer-
bations of chronic obstructive pulmonary disease (9), although 
these patients had comparable severity of dyspnea and mortal-
ity rates as the acute heart failure patients. Hence, secretoneurin 
seems to provide incremental prognostic information to estab-
lished risk indices in patients with CVD, although not being 
an unspecific biomarker of disease severity per se. This model 
is supported by the direct inhibitory effect by secretoneurin 
on diastolic Ca2+ leak via Ca2+/calmodulin-dependent protein 
kinase II δ inhibition (9) and reduced cardiomyocyte apoptosis 
and myocardial ischemia/reperfusion injury by secretoneurin 
in experimental models (11, 12). Accordingly, as cardiovascu-
lar, renal, and neuroendocrine system dysfunctions influence 
outcome in patients with severe infections (1), we hypothesized 
that secretoneurin would provide important prognostic infor-
mation in critically ill patients with infections.
MATERIALS AND METHODS
Study Design
We included patients from the two large Finnish multicenter 
studies FINNish SEPSIS (FINNSEPSIS)-study (cohort #1) 
and the FINNish Acute Lung Injury (FINNALI)-study (cohort 
#2). The FINNSEPSIS study comprised 24 ICUs, and during 
a 4-month period (November 1, 2004, to February 28, 2005), 
all adult patients (≥ 18 yr) admitted to the participating ICUs 
were screened daily for the American College of Chest Physi-
cians/Society of Critical Care Medicine criteria of severe sepsis 
and septic shock: 1) known or suspected infection, 2) two or 
more criteria for systemic inflammatory response syndrome, 
and 3) at least one new, sepsis-induced organ dysfunction 
(Fig. 1) (13). Four hundred seventy patients were included, 
and blood samples were available from 232 patients at ICU 
admission (median, 9 [Q1–Q3, 3–17] hr from study inclusion 
to sampling) and from 201 patients after 72 hours.
Cohort #2 was from the FINNALI study. During an 8-week 
period (April 16 to June 10, 2007), all patients treated with 
respiratory support more than 6 hours in 25 Finnish ICUs were 
included (14), and of the 602 patients with informed consent for 
and available blood samples at ICU admission (median, 6 [6–8] 
hr from study inclusion to sampling), 94 patients were diag-
nosed with pneumonia (n = 64) or sepsis (n = 30) by the treat-
ing physician at ICU admission (Acute Physiology and Chronic 
Health Evaluation III diagnosis group) and included in the 
current study with follow-up samples available in 78 patients 
(Fig. 1). Blood samples were stored at –80°C, and secretoneurin 
measurements were performed 
as retrospective post hoc analy-
ses with measurements final-
ized on August 25, 2010.
The primary endpoint of 
this study was hospital mortal-
ity and the secondary endpoint 
was septic shock, which were 
both reported in electronic 
clinical report forms by the 
treating physician at the time 
of death or hospital discharge. 
We recorded information on 
comorbidities and standard 
clinical and laboratory variables 
available less than 24 hours 
from patient chart records in 
both studies. The history of 
CVD was defined as previous 
coronary artery disease or heart 
failure, and this was assessed 
Fig. 1. Flowchart of the study. APACHE = Acute Physiology and Chronic Health Evaluation, FINNALI = FINNish 
Acute Lung Injury, FINNSEPSIS = FINNish SEPSIS, SN = secretoneurin.
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by the treating physician. The body mass index was calculated 
by weight (kg)/(height [m])2. The Simplified Acute Physiology 
Score (SAPS) II and the Sequential Organ Failure Assessment 
(SOFA) score were calculated after 24 hours, and we also col-
lected information on the use of inotropes during the ICU stay.
Both studies were conducted according to the Declaration 
of Helsinki and approved by the local Ethics Committees. 
Informed consent was obtained from the patient or a close 
relative before study commencement.
Biochemical Analyses
Secretoneurin was measured by an in-house radioimmunoas-
say as previously reported (7–9). The limit of detection for the 
secretoneurin assay is 50 pmol/L, and the assay has a coeffi-
cient of variation of 9% in the lower range (110 pmol/L) and 
4% in the upper range (380 pmol/L). To assess the stability of 
secretoneurin during long-term storage at –80°C, we also rean-
alyzed samples from another cohort (7) that had been stored 
for almost 7.5 years and found secretoneurin levels to be com-
parable with the measurements performed in 2008 (Supple-
mentary Fig. 1, Supplemental Digital Content 2, http://links.
lww.com/CCM/B847). We measured NT-proBNP by the Elec-
sys proBNP assay (Roche Diagnostics, Penzberg, Germany) 
(4) and chromogranin A (CgA) by a commercially available 
radioimmunoassay (EuroDiagnostica, Malmö, Sweden) (15). 
hs-TnT levels were measured by the Elecsys TNT hs STAT assay 
(Roche Diagnostics) in a subgroup of the patients with severe 
sepsis (n = 207) as previously reported (5). Cortisol was mea-
sured by an immunoassay in the patients who had not received 
corticosteroids prior to blood sampling, and free cortisol was 
calculated by the Coolens method (16). We calculated creati-
nine clearance by the Cockgroft-Gault formula (17).
Statistical Analysis
We present data as median (quartile [Q], 1–3) or absolute 
numbers and percentages. Biomarkers and other continuous 
variables deviated from the normal distribution as assessed 
by the Kolmogorov-Smirnov test and group differences were 
assessed by the Mann-Whitney U test or the chi-square test, 
and serial measurements were tested by the related-sample Wil-
coxon signed rank test. Spearman rank correlation was used to 
examine correlations between variables. The ability of secre-
toneurin to predict mortality was explored by univariate and 
multivariate logistic regression analyses with odds ratios (ORs) 
and 95% CIs. Variables associated with mortality in univariate 
analysis were included in multivariate models of both cohorts 
(backward selection). We also performed additional bivariate 
logistic regression analyses with secretoneurin and CVD and 
secretoneurin and NT-proBNP. We assessed the association 
between secretoneurin and septic shock during the hospitaliza-
tion by univariate and multivariate logistic regression. Secre-
toneurin and other variables with a right-skewed distribution 
were transformed by the natural logarithm prior to regression 
analyses. Prognostic accuracy was assessed by receiver operat-
ing characteristics (ROC) curve analysis with area under the 
curve (AUC) presented with 95% CI using a logistic model 
with hospital mortality as the response variable. The AUCs are 
from nested models and are presented accordingly (18). We also 
used ROC statistics and the Youden index J to identify the opti-
mal cutoff points of secretoneurin. The basic risk model was 
built based on the independent variables of the multivariate 
regression analysis, which is analogous to the strategy used in 
previous publications by our group (9, 15), and we examined 
calibration by calculating the category-free net reclassification 
index (NRI) (19). We also tested the optimal secretoneurin 
cutoff from the FINNSEPSIS study in patients with sepsis in 
cohort #2 by producing Kaplan-Meier plots and comparing the 
groups by the log-rank test. A p value less than 0.05 was consid-
ered statistically significant. Statistical analyses were performed 
with SPSS for Windows version 19.0 (SPSS, Chicago, IL), Med-
Calc for Windows, version 12.1.4.0 (MedCalc Software, Mar-
iakerke, Belgium), and the statistical programming language R 
(R Development Core Team, Vienna, Austria).
RESULTS
Secretoneurin Levels in Patients With Severe Sepsis 
(Cohort #1; FINNSEPSIS Study)
The prevalence of common risk factors in critically ill patients 
was higher among hospital nonsurvivors compared with survi-
vors (Supplementary Table 1, Supplemental Digital Content 2, 
http://links.lww.com/CCM/B847). The median secretoneurin 
level on study inclusion in patients with severe sepsis was 170 
pmol/L (Q1–Q3, 131–240 pmol/L). Patients with secretoneu-
rin levels over the median at ICU admission were more often 
women, had worse renal function, had higher lactate and free 
cortisol levels, had lower platelet count, had higher levels of 
admission cardiovascular biomarkers, had higher SAPS II and 
SOFA scores after 24 hours, and were more likely to need infusion 
with dobutamine and epinephrine (Table 1). Secretoneurin lev-
els at ICU admission were positively correlated with admission 
NT-proBNP, hs-TnT, CgA, cortisol and lactate levels, and SAPS 
II and SOFA scores after 24 hours and inversely correlated with 
estimated creatinine clearance (Supplementary Table 2, Supple-
mental Digital Content 2, http://links.lww.com/CCM/B847).
Predictors of Hospital Mortality in Severe Sepsis
Hospital mortality in the patients with severe sepsis was 28% 
(65/232). High secretoneurin levels at ICU admission were 
associated with increased risk of hospital mortality: OR, 3.60 
(95% CI, 1.74–7.44) (p = 0.001) (Table 2). This association was 
significant also after adjustment for other risk variables, includ-
ing history of CVD and cardiovascular biomarkers: OR, 3.17 
(1.12–9.00) (p = 0.030). In contrast, the associations between 
hospital mortality and NT-proBNP, hs-TnT, and CgA levels 
were not significant in multivariate analysis that also included 
secretoneurin. Adjusting for CVD and NT-proBNP in sepa-
rate bivariate analyses did not change the association between 
secretoneurin and hospital mortality (Supplementary Table 3, 
Supplemental Digital Content 2, http://links.lww.com/CCM/
B847). The AUC of secretoneurin to predict hospital mortality 
in patients with severe sepsis was 0.65 (95% CI, 0.57–0.73), and 
Copyright © 2016 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
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TABLE 1. Characteristics of the Patients in the Two Cohorts as Divided by the Median 
Secretoneurin Level at Admission (pmol/L)
Characteristics
Cohort #1: FINNSEPSIS Cohort #2: FINNALI Infection
Secretoneurin,  
60–170  
(n = 113)
Secretoneurin,  
170–560  
(n = 119) p
Secretoneurin,  
47–150  
(n = 46)
Secretoneurin,  
150–308  
(n = 48) p
Age (yr) 61 (51–72) 61 (49–73) 0.75 63 (57–72) 64 (55–78) 0.53
Women, n (%) 25 (22.1) 48 (40.3) 0.003 16 (34.8) 11 (22.9) 0.20
Body mass index (kg/m2)a 26 (24–28) 26 (23–29) 0.68 27 (24–29) 26 (24–28) 0.97
Cardiovascular disease,a  
n (%)
25 (22.7) 39 (33.1) 0.08 14 (31.8) 19 (39.6) 0.44
Diabetes mellitus,b n (%) 25 (24.0) 32 (28.8) 0.43 12 (27.3) 17 (35.4) 0.40
Hypertension,b n (%) 47 (44.8) 42 (38.2) 0.33 —
Chronic obstructive 
pulmonary disease,b n (%)
— 11 (25.0) 10 (20.8) 0.63
Heart rate, admission (bpm) — 81 (67–90) 94 (76–112) 0.002
Mean arterial pressure, 
admission (mm Hg)
— 78 (68–88) 72 (63–80) 0.092
Respiratory rate, admission 
(per min)
— 17 (14–21) 20 (15–23) 0.092
Creatinine clearance  
(mL/min)c
85 (59–126) 43 (25–79) < 0.001 99 (68–123) 40 (23–61) < 0.001
Peak lactate levels, < 24 hr 
(mmol/L)d
1.7 (1.1–2.6) 2.8 (1.5–4.5) < 0.001 —
Platelet count, < 24 hra 192 (116–300) 113 (52–213) < 0.001 —
Simplified Acute Physiology 
Score II score, 24 hr
39 (28–49) 48 (38–58) < 0.001 40 (31–44) 49 (41–62) < 0.001
Sequential Organ Failure 
Assessment score, 24 hr
7 (5–9) 10 (7–12) < 0.001 7 (4–8) 9 (6–13) 0.001
N-terminal pro–B-type 
natriuretic peptide, 
admission (pg/mL)a
2,982  
(826–6,955)
7,414  
(2,632–18,959)
< 0.001 3,350  
(1,061–8,150)
9,574  
(1,987–25,893)
0.001
High-sensitivity troponin T 
admission (ng/L)c
26 (13–75) 54 (29–211) < 0.001 —
Chromogranin A, admission 
(nmol/L)
6.7 (5.2–10.8) 14.7 (9.3–31.2) < 0.001 —
Free cortisol (nmol/L)e 69 (33–151) 200 (90–394) < 0.001
Dopamine infusion, n (%) 13 (12) 16 (13) 0.66 —
Dobutamine infusion, n (%) 18 (16) 34 (29) 0.02 —
Norepinephrine infusion, n (%) 81 (72) 82 (69) 0.64 —
Epinephrine infusion, n (%) 0 4 (3) 0.049 —
Hospital mortality, n (%) 20 (18) 45 (38) 0.001 7 (15) 22 (46) 0.001
FINNALI = FINNish Acute Lung Injury, FINNSEPSIS = FINNish SEPSIS.
a < 5% missing.
b < 10% missing.
c < 15% missing.
d < 20% missing.
e Available in 133 patients.
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the AUC of NT-proBNP was 0.63 (0.54–0.71) (Supplementary 
Fig. 2, Supplemental Digital Content 2, http://links.lww.com/
CCM/B847). Adding secretoneurin to age increased the AUC 
from 0.66 (0.59–0.74) to 0.71 (0.64–0.78). In contrast, the addi-
tion of NT-proBNP to age changed the AUC from 0.66 (0.59–
0.74) to 0.68 (0.60–0.75). Secretoneurin at ICU admission also 
improved the classification of patients on top of age as assessed 
by category-free NRI: 0.35 (95% CI, 0.06–0.64) (p = 0.02). 
The effect by secretoneurin was primarily to downgrade risk 
in patients considered of high risk but who did not experience 
an event during the index hospitalization (Supplementary Fig. 
3, Supplemental Digital Content 2, http://links.lww.com/CCM/
B847). In contrast, NT-proBNP did not provide a significant 
improvement in NRI: –0.03 (–0.33 to 0.26) (p = 0.82) (Supple-
mentary Fig. 4, Supplemental Digital Content 2, http://links.
lww.com/CCM/B847). The optimal secretoneurin concentra-
tion to predict hospital mortality was 175 pmol/L with sensitiv-
ity 68% and specificity 60%. Patients with secretoneurin levels 
over 175 pmol/L at ICU admission had increased risk of hos-
pital mortality (Fig. 2), also after adjustment for SAPS II score 
(OR, 2.08 [1.08–3.99]; p = 0.028) and SOFA score (OR, 2.15 
[1.12–4.11]; p = 0.022).
TABLE 2. Associations Between Variables Available on Study Inclusion and Hospital 
Mortality in the Two Cohorts
Characteristics
Cohort #1: FINNSEPSIS Cohort #2: FINNALI Infection
OR 95% CI p OR 95% CI p
Univariate analysis
 Age, per 1-yr increase 1.05 1.02–1.07 < 0.001 1.03 0.99–1.06 0.13
 Gender (female vs male) 1.70 0.93–3.10 0.08 0.92 0.35–2.44 0.87
 Body mass index, per 1-unit increase 1.00 0.93–1.06 0.87 0.97 0.90–1.05 0.48
 Cardiovascular disease 2.51 1.35–4.64 0.004 1.54 0.62–3.82 0.36
 Diabetes mellitus 2.56 1.34–4.88 0.004 1.32 0.51–3.37 0.57
 Hypertension 1.13 0.47–1.73 0.76 —
 Chronic obstructive pulmonary disease — 0.89 0.31–2.60 0.83
 Heart rate on inclusion (bpm) — 1.00 0.98–1.02 0.96
 Mean arterial pressure on inclusion (mm Hg) — 0.99 0.96–1.02 0.35
 Respiratory rate on inclusion (per min) — 1.01 0.94–1.08 0.81
 Positive blood culture 0.90 0.47–1.73 0.76 —
 Proton pump inhibitor use 1.50 0.65–3.47 0.35 —
 Creatinine clearance (mL/min) 0.45 0.29–0.71 < 0.001 0.36 0.17–0.78 0.009
 Platelet count (× 109/L) 0.82 0.60–1.14 0.24 —
 Peak lactate < 24 hr (mmol/L) 1.16 1.03–1.31 0.012 —
 Total fluid resuscitation volume < 24 hr (L) 1.05 0.98–1.14 0.19 1.09 0.91–1.32 0.36
 Steroid infusion 1.14 0.64–2.02 0.66 —
 N-terminal pro–B-type natriuretic peptide (pg/mL) 1.32 1.08–1.62 0.006 1.62 1.16–2.28 0.005
 High-sensitivity troponin T (ng/L) 1.28 1.03–1.59 0.026 —
 Chromogranin A (nmol/L) 1.87 1.30–2.68 0.001 —
 Secretoneurin (pmol/L) 3.60 1.74–7.44 0.001 16.21 3.43–76.53 < 0.001
 Sepsis (Acute Physiology and Chronic Health 
Evaluation diagnosis)
— 2.29 0.92–5.74 0.08
Multivariate analysis (variables retained in the final model)a
 Secretoneurin (pmol/L) 3.17 1.12–9.00 0.030 11.60 1.37–98.32 0.025
 Age 1.03 1.01–1.07 0.038 1.05 1.001–1.11 0.044
FINNALI = FINNish Acute Lung Injury, FINNSEPSIS = FINNish SEPSIS, OR = odds ratio.
a All variables available on study inclusion and associated with the outcome in univariate analyses in one of the cohorts were included in the multivariate models, 
that is age, history of cardiovascular disease and diabetes mellitus, lactate, creatinine clearance, and cardiovascular biomarkers.
Copyright © 2016 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
Røsjø et al
6 www.ccmjournal.org	 XXX	2016	•	Volume	XX	•	Number	XXX
Secretoneurin Levels and Septic Shock in Patients 
With Severe Sepsis
Of the 232 patients with severe sepsis, 135 patients (58%) were 
diagnosed with shock during the ICU stay. Increasing age and 
high NT-proBNP, hs-TnT, and secretoneurin levels at ICU 
admission were associated with shock in univariate analyses, 
but only secretoneurin levels and age were associated with 
septic shock in the multivariate analysis (Table 3). The ROC-
AUC of secretoneurin to predict hospital mortality in patients 
with septic shock during the hospitalization was 0.63 (95% CI, 
0.55–0.71), and the ROC-AUC to predict mortality in patients 
without shock was 0.65 (0.54–0.74).
Secretoneurin Levels and Hospital Mortality in 
Cohort #2 (FINNALI Study)
Hospital mortality in cohort #2 was 31% (29/94), and the 
median secretoneurin level on study inclusion was 150 pmol/L 
(Q1–Q3, 108–192 pmol/L). Patient characteristics according to 
mortality in cohort #2 are presented in Supplementary Table 4 
(Supplemental Digital Content 2, http://links.lww.com/CCM/
B847). Patients with secretoneurin levels over the median 
at ICU admission had worse renal function and higher NT-
proBNP levels and SOFA and SAPS II scores compared with 
the other patients (Table 1). Secretoneurin levels in this cohort 
were also positively correlated with NT-proBNP levels and 
SAPS II and SOFA scores and inversely correlated with esti-
mated creatinine clearance (Supplementary Table 5, Supple-
mental Digital Content 2, http://links.lww.com/CCM/B847).
Including the same variables into the multivariate model as 
used in cohort #1, secretoneurin levels and age were the only 
two variables independently associated with hospital mortal-
ity (Table 2). Adjusting for CVD and NT-proBNP in separate 
bivariate analyses did not change the association between 
secretoneurin and hospital mortality (Supplementary Table 3, 
Fig. 2. Mortality according to quartiles of secretoneurin (SN) measured on inclusion in the two cohorts. Mortality for septic patients in cohort #1 and #2 
stratified according to the cutoff of SN 175 pmol/L is also presented, and the groups were compared by the log-rank test. FINNALI = FINNish Acute 
Lung Injury, FINNSEPSIS = FINNish SEPSIS.
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Supplemental Digital Content 2, http://links.lww.com/CCM/
B847). The AUC of secretoneurin to predict hospital mortal-
ity in cohort #2 was 0.74 (95% CI, 0.64–0.85), and the AUC 
of NT-proBNP was 0.69 (0.58–0.81) (Supplementary Fig. 2, 
Supplemental Digital Content 2, http://links.lww.com/CCM/
B847). Adding secretoneurin to age increased the AUC from 
0.61 (0.48–0.74) to 0.76 (0.66–0.86), whereas the addition of 
NT-proBNP to age changed the AUC from 0.61 (0.48–0.74) 
to 0.68 (0.56–0.80). Secretoneurin improved the classifica-
tion of patients on top of age as assessed by category-free NRI 
(0.70 [95% CI, 0.28–1.11]; p < 0.001) with secretoneurin both 
upgrading risk in patients with subsequent events and down-
grading risk in patients with no event during the hospitaliza-
tion (Supplementary Fig. 5, Supplemental Digital Content 
2, http://links.lww.com/CCM/B847). We identified a secreto-
neurin concentration of 170 pmol/L as the optimal cutoff to 
predict hospital mortality in cohort #2, and patients with secre-
toneurin levels over 170 pmol/L had increased risk of mortal-
ity also after adjustment for SAPS II and SOFA scores, which 
both were calculated after 24 hours: OR, 6.96 (2.60–18.59) 
(p < 0.001) for both. Assessing only the patients of cohort #2 
with sepsis (n = 30), the AUC of secretoneurin to predict hos-
pital mortality (n = 13; 43%) was 0.72 (0.52–0.86). The cutoff 
of secretoneurin 175 pmol/L derived from cohort #1 was asso-
ciated with mortality in the septic patients of cohort #2 (Fig. 2) 
with sensitivity 70% and specificity 65%. There were no inter-
actions between the time of blood sampling and secretoneurin 
levels for the endpoint hospital mortality and septic shock in 
cohort #1 or #2.
Changes in Secretoneurin Levels During ICU 
Admission
We found that secretoneurin levels decreased significantly 
from study inclusion to the second timepoint for blood sam-
pling in both cohorts (Supplementary Fig. 6, Supplemental 
Digital Content 2, http://links.lww.com/CCM/B847). There 
were close correlations between secretoneurin levels measured 
on study inclusion and at later timepoints: ρ = 0.65 (cohort 
#1) and ρ = 0.74 (cohort #2) (p < 0.001) for both. Secreto-
neurin levels after 72 hours in cohort #1 separated hospital 
survivors from nonsurvivors (median, 170 [Q1–Q3, 140–240] 
vs 150 [120–173] pmol/L; p = 0.002), whereas secretoneurin 
levels after 48 hours in cohort #2 did not separate between 
survivors and nonsurvivors (129 [106–152] vs 118 [99–148] 
pmol/L; p = 0.33). The AUC of secretoneurin after 72 hours in 
cohort #1 for hospital mortality was 0.65 (95% CI, 0.58–0.71), 
whereas the AUC of secretoneurin after 48 hours in cohort #2 
for hospital mortality was 0.57 (0.45–0.68).
DISCUSSION
The main result of this study, using two separate multicenter 
cohorts of critically ill patients with infections, was the consis-
tent association between secretoneurin levels at ICU admission 
and hospital mortality and shock after adjustment for other 
TABLE 3. Association Between Variables Available on Inclusion in the Study and Septic 
Shock During the ICU Stay in the FINNish SEPSIS Study (Cohort #1)
Characteristics OR 95% CI p
Univariate analysis
 Age, per 1-yr increase 1.03 1.01–1.04 0.007
 Gender (female vs male) 0.96 0.55–1.69 0.89
 Body mass index, per 1-unit increase 1.03 0.97–1.09 0.39
 Cardiovascular disease 1.68 0.92–3.09 0.09
 Diabetes mellitus 1.07 0.58–1.97 0.84
 Hypertension 1.12 0.65–1.95 0.68
 Creatinine clearance (mL/min) 0.76 0.51–1.13 0.18
 Lactate (mmol/L) 1.06 0.95–1.20 0.30
 Platelet count (× 109/L) 0.86 0.63–1.16 0.31
 N-terminal pro–B-type peptide (pg/mL) 1.22 1.02–1.44 0.026
 High-sensitivity troponin T (ng/L) 1.26 1.03–1.54 0.022
 Chromogranin A (nmol/L) 1.39 0.99–1.95 0.059
 Secretoneurin (pmol/L) 2.13 1.11–4.08 0.023
Multivariate analysis: final model (variables retained in the final model)
 Age, yr 1.02 1.01–1.04 0.020
 Secretoneurin (pmol/L) 2.17 1.06–4.46 0.034
OR = odds ratio.
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risk variables in multivariate regression analyses. Secretoneu-
rin also improved the risk prediction as assessed by additional 
statistical indices; thus, secretoneurin seems to be a promis-
ing novel biomarker for risk prediction in critically ill patients 
with infections.
Mortality rates in patients with severe sepsis are 30–40% 
(20). Data from different cohorts of patients with severe sepsis 
have identified multiple-organ failure, refractory shock, and 
respiratory failure as the main causes of death (20). Acute myo-
cardial infarction and ventricular arrhythmias also contribute 
to mortality in severe sepsis; thus, myocardial dysfunction is 
a major contributor to mortality in critically ill patients with 
infections as also demonstrated by echocardiography (21–23). 
Pertinent to this, there is evidence that myocardial dysfunction 
in severe sepsis may be at least partly preventable, including 
experimental and retrospective studies that have found positive 
effects on mortality by β-blockers and statins (24–26). A pro-
spective single-center study also reported better outcomes in 
septic shock patients who were randomized to β-blocker infu-
sion from 24 hours after ICU admission (27); however, 28-day 
mortality was still 49% in the β-blocker group. Accordingly, a 
biomarker that at ICU admission could identify patients with 
infections at increased risk of hospital mortality and shock 
could prove helpful to help optimize the benefit-harm ratio of 
cardioprotective therapy.
To have clinical utility, a biomarker needs to add to estab-
lished risk indices and to improve patient management (28). 
Our data support secretoneurin as a prognostic biomarker 
in critically ill patients with infections as admission secreto-
neurin levels provided incremental prognostic information to 
established risk indices, including history of CVD and estab-
lished cardiovascular biomarkers. Secretoneurin levels over 
175 pmol/L also provided additional prognostic information 
to SOFA and SAPS II scores in severe sepsis and septic shock, 
and this was the case although secretoneurin measurements 
were performed early after ICU admission, and the risk scores 
were first calculated after 24 hours. We also found compara-
ble sensitivities and specificities for the cutoff of 175 pmol/L 
among septic patients in cohorts #1 and #2. Still, the design 
of this study does not permit any assumptions to be made 
whether the peptide secretoneurin itself may directly influ-
ence outcome in critically ill patients with infections (i.e., 
causal relationship with outcome) or whether secretoneurin 
merely is a risk marker that reflects pathophysiology associ-
ated with shock and mortality. Our study was neither designed 
to assess whether secretoneurin measurements may improve 
patient management; however, patients with high secreto-
neurin levels, and thus presumably also increased systemic 
and myocardial stress, could be the patients who benefit the 
most from cardioprotective therapy. The associations between 
secretoneurin and neuroendocrine and myocardial dysfunc-
tion in our patients are supported by the significant correla-
tions between secretoneurin levels and levels of free cortisol 
and established cardiovascular biomarkers, the independent 
association between admission secretoneurin levels and shock 
in cohort #1, and the increased need for dobutamine and 
epinephrine infusion during the ICU stay for patients with 
high admission secretoneurin levels. Of note, impaired renal 
function also seems to increase circulating secretoneurin lev-
els, and this could explain part of the prognostic utility of 
secretoneurin in critically ill patients with infections. Thus, it 
is possible that secretoneurin may also prove valuable for early 
detection of renal injury and failure, but this will have to be 
assessed in additional studies.
The strengths of our study are the use of two separate large 
multicenter cohorts of critically ill patients with infections 
and the comparable results in both cohorts. Limitations of the 
study are the lack of cardiac imaging and no adjudication of 
cause of death. Cohort #2 included patients with infections 
and respiratory failure, but we also validated the cutoff for 
mortality in severe sepsis and septic shock from cohort #1 in 
comparable patients in cohort #2.
CONCLUSIONS
Secretoneurin seems to be a biomarker that provides strong 
and complementary prognostic information to established risk 
indices in critically ill patients with infections.
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